TY  - JOUR
T1  - The Importance of MTHFD2 Expression in Renal Cell Carcinoma
TT  - The Importance of MTHFD2 Expression in Renal Cell Carcinoma
AU  - Ceylan, Onur
AU  - Arslan, Remzi
PY  - 2025
DA  - October
Y2  - 2025
DO  - 10.33719/nju1594236
JF  - The New Journal of Urology
JO  - New J Urol
PB  - Ali İhsan TAŞÇI
WT  - DergiPark
SN  - 3023-6940
SP  - 121
EP  - 129
VL  - 20
IS  - 3
LA  - en
AB  - Objective: Renal cell carcinoma (RCC) carries a poor prognosis at advanced stages. Identifying reliable prognostic biomarkers is essential for improved clinical management. Methylenetetrahydrofolate dehydrogenase 2 (MTHFD2), a key mitochondrial enzyme in the folate cycle, is overexpressed in various rapidly proliferating malignancies. However, its prognostic value in RCC remains underexplored. For this reason, we purposed to search the prognostic role of MTHFD2 expression in RCC.Materials and Methods: This study included 124 RCC patients who applied radical nephrectomy between 2015 and 2020. Immunohistochemical analysis of MTHFD2 expression was performed on paraffin-embedded tumor samples. Expression levels were classified using a histoscore-based system: low (grades 0–1) and high (grades 2–3). Correlations between MTHFD2 expression and clinical/pathological parameters were evaluated, and survival analysis was conducted.Results: MTHFD2 overexpression was detected in 53% of tumors and was absent in adjacent non-tumor tissues. High expression was significantly associated with adverse prognostic features, including higher histological grade, sarcomatoid differentiation, advanced pT stage, and presence of distant metastases (all p < 0.05). Patients with high MTHFD2 expression had significantly reduced overall survival (p < 0.001). Remarkably, early-stage tumors (pT1–2) with high MTHFD2 expression were linked to shorter survival compared to more advanced tumors (pT3–4) with low expression.Conclusion: Our results pointed out that high expression of MTHFD2 is associated with poor prognosis in RCC and may function as an independent prognostic biomarker. These findings underscore the potential of MTHFD2 in risk stratification and as a therapeutic target in RCC.
KW  - MTHFD2
KW  - renal cell carcinoma
KW  - prognostic marker
KW  - immunohistochemical study
CR  - Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. https://doi.org/10.3322/caac.21442
CR  - Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67(5):913–24. https://doi.org/10.1016/j.eururo.2015.01.005
CR  - Noone A, Howlader N, Krapcho M, Miller D, Brest A, Yu M, et al. SEER cancer statistics review, 1975–2015. Bethesda (MD): National Cancer Institute; 2018. Available from: https://seer.cancer.gov/csr/1975_2015/
CR  - Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med. 2017;376(4):354–66. https://doi.org/10.1056/NEJMra1601333
CR  - Newman AC, Maddocks ODK. One-carbon metabolism in cancer. Br J Cancer. 2017;116(12):1499–504. https://doi.org/10.1038/bjc.2017.118
CR  - Nilsson R, Jain M, Madhusudhan N, Sheppard NG, Strittmatter L, Kampf C, et al. Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer. Nat Commun. 2014;5:3128. https://doi.org/10.1038/ncomms4128
CR  - Shin M, Bryant JD, Momb J, Appling DR. Mitochondrial MTHFD2L is a dual redox cofactor-specific methylenetetrahydrofolate dehydrogenase/methenyltetrahydrofolate cyclohydrolase expressed in both adult and embryonic tissues. J Biol Chem. 2014;289(22):15507–17. https://doi.org/10.1074/jbc.M114.555573
CR  - Nilsson R, Nicolaidou V, Koufaris C. Mitochondrial MTHFD isozymes display distinct expression, regulation, and association with cancer. Gene. 2019;716:144032. https://doi.org/10.1016/j.gene.2019.144032
CR  - He Z, Wang X, Zhang H, Liang B, Zhang J, Zhang Z, et al. High expression of folate cycle enzyme MTHFD1L correlates with poor prognosis and increased proliferation and migration in colorectal cancer. J Cancer. 2020;11(14):4213–21. https://doi.org/10.7150/jca.35014
CR  - Liu F, Liu Y, He C, Tao L, He X, Song H, et al. Increased MTHFD2 expression is associated with poor prognosis in breast cancer. Tumour Biol. 2014;35(9):8685–90. https://doi.org/10.1007/s13277-014-2144-2
CR  - Green NH, Galvan DL, Badal SS, Chang BH, LeBleu VS, Long J, et al. MTHFD2 links RNA methylation to metabolic reprogramming in renal cell carcinoma. Oncogene. 2019;38(34):6211–25. https://doi.org/10.1038/s41388-019-0869-4
CR  - Lee D, Xu IM, Chiu DK, Lai RK, Tse AP, Li LL, et al. Folate cycle enzyme MTHFD1L confers metabolic advantages in hepatocellular carcinoma. J Clin Invest. 2017;127(5):1856–72. https://doi.org/10.1172/JCI91015
CR  - Compérat EM, Burger M, Gontero P, Mostafid AH, Palou J, Rouprêt M, et al. Grading of urothelial carcinoma and the new WHO classification of tumours of the urinary system and male genital organs 2016. Eur Urol Focus. 2019;5(3):457–66. https://doi.org/10.1016/j.euf.2018.01.009
CR  - Lin H, Huang B, Wang H, Liu X, Hong Y, Qiu S, et al. MTHFD2 overexpression predicts poor prognosis in renal cell carcinoma and is associated with cell proliferation and vimentin-modulated migration and invasion. Cell Physiol Biochem. 2018;51(2):991–1000. https://doi.org/10.1159/000495380
CR  - Silva RV, Berzotti LA, Laia MG, Araújo LS, Silva CA, Ribeiro R, et al. Implications of MTHFD2 expression in renal cell carcinoma aggressiveness. PLoS One. 2024;19(2):e0299353. https://doi.org/10.1371/journal.pone.0299353
CR  - Ju H-Q, Lu Y-X, Chen D-L, Zuo Z-X, Liu Z-X, Wu Q-N, et al. Modulation of redox homeostasis by inhibition of MTHFD2 in colorectal cancer: mechanisms and therapeutic implications. JNCI J Natl Cancer Inst. 2019;111(6):584–96. https://doi.org/10.1093/jnci/djy161
CR  - Miyo M, Konno M, Colvin H, Nishida N, Koseki J, Kawamoto K, et al. The importance of mitochondrial folate enzymes in human colorectal cancer. Oncol Rep. 2017;37(1):417–25. https://doi.org/10.3892/or.2016.5289
CR  - Liu X, Huang Y, Jiang C, Ou H, Guo B, Liao H, et al. Methylenetetrahydrofolate dehydrogenase 2 overexpression is associated with tumor aggressiveness and poor prognosis in hepatocellular carcinoma. Dig Liver Dis. 2016;48(8):953–60. https://doi.org/10.1016/j.dld.2016.03.022
UR  - https://doi.org/10.33719/nju1594236
L1  - https://dergipark.org.tr/tr/download/article-file/4407001
ER  -